AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04581746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire
Description: bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
Study NCT04200924 — intervention group
Intervention type: OTHER
Intervention: Biodex Balance System
Description: For the computerized evaluation of postural control, Biodex Balance System will be used.
Study NCT04200924 — intervention group
Intervention type: OTHER
Intervention: Balance Error Scoring System (BESS)
Description: For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
Study NCT02745405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat Suit
Description: Participants wear a fat suit.
Study NCT02745405 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Participants wear same clothing as intervention, but in their own size.
Study NCT03022630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Palliative Care services
Description: Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
Study NCT03022630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual hepatic care
Description: Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
Study NCT04649554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate treatment
Description: Ablation
Study NCT02149160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRM-0334
Study NCT01891461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
Study NCT03207503 — intervention group
Intervention type: PROCEDURE
Intervention: fMRI
Description: Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
Study NCT02149160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00924651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: home based walking and progressive resistance training exercise
Study NCT04345185 — intervention group
Intervention type: OTHER
Intervention: Infant egg consumption (i.e., age of introduction and frequency of intake)
Study NCT03879109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy FOLFIRINOX, 6 cycles
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)
Study NCT03879109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy FOLFIRINOX, 6 cycles
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)
Study NCT01355406 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FlexStent® Femoropopliteal Self Expanding Stent System
Description: Transcatheter over guidewire placement of an intravascular stent(s)
Study NCT02132221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
Study NCT03540823 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Description: Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Study NCT03540823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Description: Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Study NCT03028493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original SAFE Intervention
Description: A CDC recommended, evidence-based falls prevention intervention.
Study NCT03028493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted SAFE Intervention
Description: An adapted version of the SAFE intervention meant to target older adults with low vision.
Study NCT00230321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
Study NCT01088308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High rate atrial and vetricular stimulation
Description: The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
Study NCT01088308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventricular Tachycardia induction
Description: A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
Study NCT04063111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum assistant closure
Description: Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
Study NCT04063111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL DRESSING
Description: CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
Study NCT03879109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Description: Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
Study NCT04680884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental for steroid
Description: 2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
Study NCT04680884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental for antifungals
Description: IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
Study NCT04680884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental for steroids and antifungals
Description: IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
Study NCT03879109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)
Study NCT03879109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)
Study NCT04134871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group walk and one to one coaching
Description: Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
Study NCT01595828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Study NCT03022175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR741
Description: SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days.
Study NCT03022175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Study NCT00972738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
Study NCT00972738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: loratadine
Description: Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
Study NCT02322593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-118 plus Oxaliplatin
Study NCT02220686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Offer and Report Protocol
Description: Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
Study NCT00972738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: placebo tablet orally once daily at bedtime for 2 weeks
Study NCT00934882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
Study NCT03568903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive physical therapy
Description: Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
Study NCT02951650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberonics VNS
Description: Vagus nerve stimulation
Study NCT04680884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
Study NCT05086822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: Irinotecan liposome
Study NCT01622101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thermogenic properties of Zantrex-3®
Description: The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
Study NCT01622101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thermogenic properties of Zantrex-3®
Description: The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
Study NCT03931837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet: Systolic blood pressure + 75 mmHg
Description: Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
Study NCT03931837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet: Systolic blood pressure + 100 mmHg
Description: Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
Study NCT03931837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet: Systolic blood pressure + 150 mmHg
Description: Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
Study NCT02216409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Study NCT02357992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SABR)
Description: SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
Study NCT01319955 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
Study NCT03238469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
Study NCT02219542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: transversus abdominis plane block
Description: transversus abdominis plane block with 20 mL saline
Study NCT01319955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
Study NCT01419990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 300 mg oral capsules, qd, 10 days
Study NCT03729596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate
Study NCT02322593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 plus Cisplatin
Study NCT01419990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 450 mg oral capsules, qd, 10 days
Study NCT01419990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules, qd, 10 days
Study NCT02571413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: score before teaching
Description: score the check-point of correct INCS usage before teaching
Study NCT02219542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transversus abdominis plane block
Description: transversus abdominis plane block with 20 mL 0.25% ropivacaine
Study NCT00835978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
Study NCT02571413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: score immediately after teaching
Description: score the check-point of correct INCS usage immediately after teaching
Study NCT02571413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: score 3 months after teaching
Description: score the check-point of correct INCS usage 3 months after teaching
Study NCT00835978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: axitinib 5mg BID (open-label) + placebo dose titration (blinded)
Study NCT04036617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaQuinate
Description: SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
Study NCT04036617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
Study NCT00835978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: axitinib 5mg BID (open-label)
Study NCT01046318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262
Description: OPC-262 5 mg will be orally administered once daily fro 52 weeks.
Study NCT01175928 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
Study NCT01175928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NormaTec PCD (Peristaltic Pulse PCD)
Description: Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
Study NCT02638181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculectomy
Study NCT01701700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: portable electronic magnifier
Study NCT01701700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: optical aids
Study NCT01701700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optical aids
Study NCT05191082 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.